Maybe it takes a certain set of experiences like going to medical school and then having cancer, or geekiness, to get excited by spending two days at a biotech conference on companion diagnostics, CDx ...

The FDA has approved Foundation Medicine's FoundationOne CDx, the first-of-a-kind comprehensive companion diagnostic test for solid tumors. The test looks for hundreds of cancer genes, providing ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that UnitedHealthcare (UHC) now covers the Guardant360® CDx liquid biopsy test for patients enrolled in its ...

Assay will predict which patients are best suited to the therapeutic that targets the steroid sulfatase enzyme. bioMérieux agreed to develop a companion test for Ipsen’s Phase I breast cancer drug ...

(RTTNews) - Guardant Health, Inc. (GH) said Thursday that the U.S. Food and Drug Administration has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic for patients with BRAF ...

Will NGS Play a Role? Companion diagnostics (CDx), in vitro diagnostic devices or imaging tools that provide information essential to the safe and effective use of a corresponding therapeutic product, ...

bioMerieux and Ipsen announced that they have signed an agreement by which bioMerieux will develop a companion test for a new breast cancer drug undergoing clinical evaluation by Ipsen. The ...

U.S. regulators on Friday granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British drugmaker AstraZeneca PLC. The drug is for women whose ...

The age of precision medicine, with treatments targeted to specific patients based on a companion test identifying the need for such a treatment, is pushing the US Food and Drug Administration (FDA) ...

GERMANTOWN, Md. & HILDEN, Germany & SAN DIEGO--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Denovo Biopharma LLC today announced a collaboration to develop a blood-based ...